An Open-Label, Randomized, Single-Dose, 2-Period, Crossover, Relative Bioavailability Study Comparing Two Formulations of ORIC-101 in Healthy Adult Subjects.
This is an open-label, randomized, 2-way crossover, relative BA study under fasting conditions. On Day 1 of each period, a single dose of ORIC-101, as either a capsule formulation (Treatment A) or a tablet formulation (Treatment B), will be administered. Pharmacokinetic (PK) sampling will be conducted predose and up to 216 hours postdose. There will be a washout period of 10 days between doses.